AL 3789 clinical trials
How each study uses AL 3789 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AL 3789 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMDTerminatedPhase 3Alcon ResearchNCT00065728Written as Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mLHow we know
- 24 Hour IOP Lowering Efficacy of AL-3789CompletedPhase 2Alcon ResearchNCT00643669Written as AL-3789 Sterile SuspensionHow we know
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedPhase 3Alcon ResearchNCT00307398Written as Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mgHow we know